MedComm · 2026
Dysregulation of Farnesoid X Receptor on Neutrophil Homeostasis Exacerbates Intestinal Inflammation via the mTORC1-Glycolysis Signaling Pathway.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Kang Dengfeng, Li Ai, Xie Xiangqi, Liu Han, Chen Liang, Feng Zhongsheng, Gao Xiang, Gao Han, Wu Xiaohan, Lu Huiying, Li Xiaoyu, Hua Jinghan, Ju Long, Lian Haifeng, Li Xue, Liu Zhanju
Аннотация
Neutrophils significantly accumulate within the inflamed intestinal mucosa of patients with inflammatory bowel disease (IBD), where the farnesoid X receptor (FXR) is typically downregulated. However, the mechanisms by which FXR modulates neutrophil-mediated mucosal inflammation in IBD remain elusive. Here, we demonstrated that FXR expression is markedly decreased in neutrophils from patients with active IBD. Fxr -/- mice exhibited exacerbated colitis following DSS insults or Citrobacter rodentium infection, evidenced by heightened neutrophil-driven immune responses including increased neutrophil infiltration and neutrophil extracellular trap (NET) formation. Adoptive transfer of Fxr -/- neutrophils into WT recipients exacerbated DSS-induced intestinal inflammation, indicating that FXR suppresses the pathogenic activity of neutrophils in a neutrophil-intrinsic manner. An ex vivo functional assay revealed that Fxr -/- neutrophils display elevated ROS production, NET formation, and migratory capacity upon inflammatory challenge. Mechanistically, RNA-sequencing and functional assays revealed enhanced mTORC1 signaling and glycolysis in Fxr -/- neutrophils. Consistently, pharmacological activation of FXR with INT-747 significantly restrained the mTORC1-glycolysis-mediated proinflammatory responses in neutrophils from IBD patients. Our findings identify FXR as a critical regulator of neutrophil-mediated mucosal inflammation via the mTORC1-glycolysis pathway, highlighting its therapeutic potential in IBD.